EPB0250 Efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in antiretroviral therapy (ART)-naive adolescents living with HIV-1: DANCE study Week 96 resultsE-posterAntiretroviral therapies and clinical issues in infants, children and adolescents
EPB0251 Improved viral load suppression with transition to pediatric dolutegravir among ART-experienced children in Kenya and Cote d’IvoireE-posterAntiretroviral therapies and clinical issues in infants, children and adolescents
EPB0252 Improved virologic suppression in children living with HIV under the age of 5 in Tanzania after the initiation of a viremia clinic and pediatric dolutegravirE-posterAntiretroviral therapies and clinical issues in infants, children and adolescents
EPB0253 Integrase inhibitor use in children living with HIV in Europe & Thailand over the last decade (2010-2020): uptake and virological responseE-posterAntiretroviral therapies and clinical issues in infants, children and adolescents
EPB0254 Effectiveness of caregiver mentor directly observed treatment and support model on viral load suppression among children and adolescents living with HIV in UgandaE-posterAntiretroviral therapies and clinical issues in infants, children and adolescents
EPB0255 High Prevalence of low level viremia among infants initiated on antiretroviral drugs following Mother to Child Transmission of HIVE-posterAntiretroviral therapies and clinical issues in infants, children and adolescents
EPB0256 Dolutegravir in our youngest cohort: follow-up of genotype led antiretroviral optimization in unsuppressed childrenE-posterAntiretroviral therapies and clinical issues in infants, children and adolescents
EPB0257 Viral load suppression in children living with HIV after pediatric dolutegravir optimization in EswatiniE-posterAntiretroviral therapies and clinical issues in infants, children and adolescents
EPB0258 High acceptability and preference for pediatric dolutegravir 10mg among children living with HIV in Nigeria at 1- and 6-month follow up, an observational studyE-posterAntiretroviral therapies and clinical issues in infants, children and adolescents
EPB0259 Outcomes from the Transitioning children to Optimal Regimens of Paediatric Dolutegravir (TORPEDO) study at 6 months in Benin, Nigeria, and UgandaE-posterAntiretroviral therapies and clinical issues in infants, children and adolescents
371 - 380 of 1427 items